These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 8083490)

  • 1. [Ophthalmologic manifestations in spinal cord diseases caused by HTLV-I virus. Clinical study of 30 cases].
    Merle H; Smadja D; Bera O; Cabre P; Vernant JC
    J Fr Ophtalmol; 1994; 17(6-7):403-13. PubMed ID: 8083490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular manifestations in patients with HTLV-I associated infection--a clinical study of 93 cases.
    Merle H; Smadja D; Le Hoang P; Bera O; Cabre P; Landau M; Vernant JC
    Jpn J Ophthalmol; 1996; 40(2):260-70. PubMed ID: 8876397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTLV-I associated retinochoroidal degeneration.
    Ohba N; Nakao K; Isashiki Y
    Jpn J Ophthalmol; 1996; 40(1):71-8. PubMed ID: 8739503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathologies associated with HTLV-1 virus in Dakar (1992-1995)].
    Michel P; Develoux M; Talarmin F; Ndiaye P; Ndiaye M; Raphenon G; Le Guenno B; Gessain A
    Med Trop (Mars); 1996; 56(3):249-54. PubMed ID: 9026591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult T-cell leukemia-lymphoma: a clinico-pathologic study of twenty-six patients from Martinique.
    Plumelle Y; Pascaline N; Nguyen D; Panelatti G; Jouannelle A; Jouault H; Imbert M
    Hematol Pathol; 1993; 7(4):251-62. PubMed ID: 8113152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV/HTLV-I coinfection and clinical grade at diagnosis.
    Chavance M; Neisson-Vernant C; Quist D; Monplaisir N; Armengaud B; Chout R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jan; 8(1):91-5. PubMed ID: 8548352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurological symptoms and disability in HTLV-1 associated myelopathy].
    Carod-Artal FJ; Mesquita HM; Ribeiro Lda S
    Neurologia; 2008 Mar; 23(2):78-84. PubMed ID: 18322825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T-cell leukemia virus type-1 uveitis. Accumulation of the human T-cell leukemia virus type-1-infected cells and constitutive expression of viral and interleukin-6 messenger ribonucleic acids.
    Ono A; Mochizuki M; Yamaguchi K; Miyata N; Watanabe T
    Invest Ophthalmol Vis Sci; 1997 Mar; 38(3):676-89. PubMed ID: 9071222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed spinal cord injury following electrical burns: a 7-year experience.
    Ko SH; Chun W; Kim HC
    Burns; 2004 Nov; 30(7):691-5. PubMed ID: 15475144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral uveitis in a rabbit experimentally infected with human T-lymphotropic virus type I.
    Taguchi H; Sawada T; Fukushima A; Iwata J; Ohtsuki Y; Ueno H; Miyoshi I
    Lab Invest; 1993 Sep; 69(3):336-9. PubMed ID: 8377474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nationwide survey of necrotizing myelopathy associated with malignancy in Japan].
    Nakagawa M; Kubota R; Takenaga S; Nakamura A; Osame M
    Rinsho Shinkeigaku; 1991 May; 31(5):512-5. PubMed ID: 1934764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
    Nishiura Y; Nakamura T; Fukushima N; Nakamura H; Ida H; Aramaki T; Eguchi K
    Antivir Ther; 2009; 14(4):533-42. PubMed ID: 19578238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
    Blejer JL; Saguier MC; Salamone HJ; Carreras LA
    Sangre (Barc); 1995 Dec; 40(6):447-51. PubMed ID: 8850226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Sjögren's syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients.
    Nakamura H; Kawakami A; Tominaga M; Hida A; Yamasaki S; Migita K; Kawabe Y; Nakamura T; Eguchi K
    J Lab Clin Med; 2000 Feb; 135(2):139-44. PubMed ID: 10695658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Episcleritis associated with pigmentary retinal degeneration in an HTLV-I carrier.
    Nomura E; Kimura T; Yabuki K; Kurita M; Goto K; Ohno S
    Tokai J Exp Clin Med; 1998 Oct; 23(4):183-5. PubMed ID: 10359508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus.
    Akimoto M; Matsushita K; Suruga Y; Aoki N; Ozaki A; Uozumi K; Tei C; Arima N
    J Rheumatol; 2007 Sep; 34(9):1841-8. PubMed ID: 17696273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular manifestations in Japanese patients with human immunodeficiency virus infection.
    Nagata Y; Fujino Y; Matsumoto S; Nishi M; Ono A; Mochizuki M; Oka S; Kimura S; Shimada K
    Jpn J Ophthalmol; 1993; 37(3):275-81. PubMed ID: 8295365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of rapidly progressive HTLV-I-associated myelopathy (HAM)].
    Kida H; Nakagawa M; Iwasaki H; Moritoyo T; Kawabata M; Arimura K; Osame M
    Rinsho Shinkeigaku; 1997 Sep; 37(9):802-5. PubMed ID: 9430994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatological findings of human T lymphotropic virus type 1 (HTLV-I)-associated myelopathy/tropical spastic paraparesis.
    Lenzi ME; Cuzzi-Maya T; Oliveira AL; Andrada-Serpa MJ; Araújo AQ
    Clin Infect Dis; 2003 Feb; 36(4):507-13. PubMed ID: 12567310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased prevalence of human T cell lymphotropic virus type 1 in patients attending a Brazilian dermatology clinic.
    Nobre V; Guedes AC; Proietti FA; Martins ML; Nassif G; Serufo JC; Lambertucci JR;
    Intervirology; 2007; 50(4):316-8. PubMed ID: 17622792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.